Table 1.
Clinical and Pathological Features of Patients in the Study Cohort
| Variables | Total Cohort | Training Cohort | Validation Cohort | p |
|---|---|---|---|---|
| n=16,972 | n=11,918 | n=5054 | ||
| Age (%) | ||||
| <64 years | 10,656 (62.8) | 7477 (62.7) | 3179 (62.9) | 0.521 |
| 64–76 years | 4532 (26.7) | 3205 (26.9) | 1327 (26.3) | |
| >76 years | 1784 (10.5) | 1236 (10.4) | 548 (10.8) | |
| Tumour site (%) | ||||
| Npple/central | 959 (5.7) | 676 (5.7) | 283 (5.6) | 0.766 |
| Upper-inner | 2620 (15.4) | 1857 (15.6) | 763 (15.1) | |
| Lower-inner | 945 (5.6) | 659 (5.5) | 286 (5.7) | |
| Upper-outer | 5575 (32.8) | 3883 (32.6) | 1692 (33.5) | |
| Lower-outer | 1271 (7.5) | 909 (7.6) | 362 (7.2) | |
| Others | 5602 (33.0) | 3934 (33.0) | 1668 (33.0) | |
| Laterality (%) | ||||
| Left | 8465 (49.9) | 5898 (49.5) | 2567 (50.8) | 0.125 |
| Right | 8507 (50.1) | 6020 (50.5) | 2487 (49.2) | |
| Histology (%) | ||||
| Duct | 14,467 (85.2) | 10,135 (85.0) | 4332 (85.7) | 0.631 |
| Lobular | 1136 (6.7) | 803 (6.7) | 333 (6.6) | |
| Duct+lobular | 564 (3.3) | 400 (3.4) | 164 (3.2) | |
| Others | 805 (4.7) | 580 (4.9) | 225 (4.5) | |
| Grade (%) | ||||
| Grade1 | 4106 (24.2) | 2867 (24.1) | 1239 (24.5) | 0.217 |
| Grade2 | 7803 (46.0) | 5500 (46.1) | 2303 (45.6) | |
| Grade3 | 5030 (29.6) | 3533 (29.6) | 1497 (29.6) | |
| Grade4 | 33 (0.2) | 18 (0.2) | 15 (0.3) | |
| Summary stage (%) | ||||
| Local | 11,925 (70.3) | 8355 (70.1) | 3570 (70.6) | 0.66 |
| Regional | 4645 (27.4) | 3274 (27.5) | 1371 (27.1) | |
| Distant | 402 (2.4) | 289 (2.4) | 113 (2.2) | |
| T_stage (%) | ||||
| T1 | 10,128 (59.7) | 7096 (59.5) | 3032 (60.0) | 0.939 |
| T2 | 5426 (32.0) | 3818 (32.0) | 1608 (31.8) | |
| T3 | 949 (5.6) | 672 (5.6) | 277 (5.5) | |
| T4 | 469 (2.8) | 332 (2.8) | 137 (2.7) | |
| N_stage (%) | ||||
| N0 | 12,252 (72.2) | 8592 (72.1) | 3660 (72.4) | 0.852 |
| N1 | 3576 (21.1) | 2526 (21.2) | 1050 (20.8) | |
| N2 | 716 (4.2) | 496 (4.2) | 220 (4.4) | |
| N3 | 428 (2.5) | 304 (2.6) | 124 (2.5) | |
| Surg prim site (%) | ||||
| No | 602 (3.5) | 425 (3.6) | 177 (3.5) | 0.873 |
| Yes | 16,370 (96.5) | 11,493 (96.4) | 4877 (96.5) | |
| Tumour size (%) | ||||
| <2 cm | 9558 (56.3) | 6689 (56.1) | 2869 (56.8) | 0.719 |
| 2~5 cm | 6070 (35.8) | 4285 (36.0) | 1785 (35.3) | |
| >5 cm | 1343 (7.9) | 943 (7.9) | 400 (7.9) | |
| Bone_metastasis (%) | ||||
| No | 16,749 (98.7) | 11,759 (98.7) | 4990 (98.7) | 0.779 |
| Yes | 223 (1.3) | 159 (1.3) | 64 (1.3) | |
| Brain_metastasis (%) | ||||
| No | 16,966 (100.0) | 11,912 (99.9) | 5054 (100.0) | 0.251 |
| Yes | 6 (0.0) | 6 (0.1) | 0 (0.0) | |
| Liver_metastasis (%) | ||||
| No | 16,948 (99.9) | 11,902 (99.9) | 5046 (99.8) | 0.875 |
| Yes | 24 (0.1) | 16 (0.1) | 8 (0.2) | |
| Lung_metastasis (%) | ||||
| No | 16,922 (99.7) | 11,882 (99.7) | 5040 (99.7) | 0.904 |
| Yes | 50 (0.3) | 36 (0.3) | 14 (0.3) | |
| Subtype (%) | ||||
| HR-/HER2- | 1396 (8.2) | 991 (8.3) | 405 (8.0) | 0.503 |
| HR-/HER2+ | 869 (5.1) | 607 (5.1) | 262 (5.2) | |
| HR+/HER2- | 12,866 (75.8) | 9003 (75.5) | 3863 (76.4) | |
| HR+/HER2+ | 1841 (10.8) | 1317 (11.1) | 524 (10.4) | |
| ER (%) | ||||
| Negative | 2399 (14.1) | 1698 (14.2) | 701 (13.9) | 0.535 |
| Positive | 14,573 (85.9) | 10,220 (85.8) | 4353 (86.1) | |
| PR (%) | ||||
| Negative | 4092 (24.1) | 2876 (24.1) | 1216 (24.1) | 0.936 |
| Positive | 12,880 (75.9) | 9042 (75.9) | 3838 (75.9) | |
| HER2 (%) | ||||
| Negative | 14,262 (84.0) | 9994 (83.9) | 4268 (84.4) | 0.348 |
| Positive | 2710 (16.0) | 1924 (16.1) | 786 (15.6) | |
| Month (median [IQR]) | 47.00 [25.00, 72.00] | 46.00 [24.00, 72.00] | 48.00 [25.00, 73.00] | 0.039 |
Abbreviations: HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; PR, progesterone receptor.